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SUMMARY : To assess the efficacy and possible potential side effects of alternate 
routes of treatment, 2.5mg bromocriptine was administered vaginally or rectally to five 
normoprolactinemic and four idiopathic hyperprolactinemic women. 
 Serum bromocriptine and prolactin (PRL) levels were measured hourly for the first 12 
hours, then every 2 hours for the following 12 hours. The mean peak bromocriptine levels 
were 641.0 ± 200.1 pg/ml and 386.5 ± 134.8 pg/ml in the normoprolactinemic and 
hyperprolactinemic groups, respectively. Maximum PRL reduction rate was 67.7 ± 3.4% 
at 11.3 ± 1.1 hours and 44.8 ± 0.7% at 21.5 ± 1.5 hours after vaginal administration in the 
normoprolactinemic and hyperprolactinemic groups, respectively. 
 In contrast, in the rectal treatment group the mean peak values of serum bromocriptine 
were 364 pg/ml and 314.5 ± 3.9 pg/ml in the normoprolactinemic and hyperprolactinemic 
groups, respectively. Maximum PRL reduction rate was 38.1% at 8 hours and 21.0 ± 10.4% 
at 17.0 ± 3.5 hours in the normoprolactinemic and hyperprolactinemic gryoups, respectively. 
In conclusion, we suggest that the vaginal route of administration is as effective and has 
fewer side effects than by the oral route. Furthermore, the rectal route is an alternate 
method of treatment for patients who cannot be administered bromocriptine by vaginal 
route.
       INTRODUCTION 
 Oral bromocriptine is one method of treat-
ment that has been proven effective in the 
treatment of hyperprolactinemic and normo-
prolactinemic women. However, the gastrointes-
tinal side effects associated with oral adminis-
tration of bromocriptine remain a problem. 
Recently, it has been suggested that vaginal 
administration of bromocriptine may reduce the 
side effects associated with oral administration 
(1, 2). In this study, a single 2.5mg tablet of 
bromocriptine was administered by either the 
vaginal or rectal route, and bromocriptine, and
prolactin (PRL) concentrations in blood were 
measured to assess the efficacy and tolerance 
of these alternate routes. 
   MATERIALS AND METHODS 
 The study group consisted of five normopro-
lactinemic and four idiopathic hyperpro-
lactinemic female subjects. In the normopro-
lactinemic group, four subjects were admin-
istered 2.5mg bromocriptine vaginally during the 
follicular phase (7-10th day of the menstrual 
cycle) and the remaining one subject was 
administered 2.5mg bromocriptine rectally. In 
the hyperprolactinemic group, two subjects were
administered 2.5mg bromocriptine vaginally 
and two subjects were administered 2.5mg 
bromocriptine rectally. Blood samples were 
obtained prior to treatment, then every hour for 
the first 12 hours and every 2 hours for the 
following 12 hours after bromocriptine admin-
istration. Bromocriptine and PRL concentra-
tions in blood were measured by radio-
immunoassay. All symptoms and side effects 
following bromocriptine administration were 
also recorded.
          RESULTS 
 Table 1 shows blood levels of bromocriptine 
following vaginal administration of bromo-
criptine. Bromocriptine in blood was initially 
detectable at 3.8 ± 0.6 hours and 3.0 ± 0.7 hours 
after vaginal administration in the normopro-
lactinemic and hyperprolactinemic groups, 
respectively. Mean peak bromocriptine level 
was reached at 10.3 + 1.7 hours and 14.5 ± 1.8 
hours after vaginal administration and the 
values were 641.0 ± 200.1 pg/ml and 386.5 ± 134.8 
pg/ml in the normoprolactinemic and the 
hyperprolactinemia groups, respectively. The 
hyperprolactinemic group required a greater 
length of time to reach peak level than the 
normoprolactinemic group. Bromocriptine 
concentrations in blood at 24 hours after vaginal
administration were 187.0 ± 63.0 pg/ml and 
75.5 ± 6.3 pg/ml in the normoprolactinemic and 
gyperprolactinemic groups, respectively. The 
normoprolactinemic group demonstrated a 
higher blood concentration of bromocriptine 
than the hyperprolactinemic group at peak level 
and at 24 hours after vaginal administration.
 Table 2 presents blood levels of bromocriptine 
following rectal administration of bromo-
criptine. Bromocriptine in blood was initially 
detectable at 1 hour and 5.5 ± 3.2 hours after 
rectal administration in the normoprolactinemic 
and hyperprolactinemic groups, respectively. 
The mean peak bromocriptine level was reached 
at 7 hours and 10.0 ± 5.7 hours and the values 
were 364 pg/ml and 314.5 ± 3.9 pg/ml in the 
normoprolactinemic and hyperprolactinemic 
groups, respectively. Blood concentration of 
bromocriptine at 24 hours after rectal admin-
istration was 37 pg/ml and 192 pg/ml in the 
normoprolactinemic and hyperprolactinemic 
groups, respectively, but bromocriptine was not 
detectable in one hyperprolactinemic subject.
Table 1. Serum bromocriptine pharmacokinetics after vaginal administration of 2.5mg 
        bromocriptine (Mean±SE) 
                            Normoprolactinemia Hyperprolactinemia 
                                 (n=4) (n=2) 
 Initial detection (h) 3.8±0.6 (3^-6) 3.0±0.7 (2-4) 
 Time to peak (h) 10.3±1.7 (4-16) 14.5±1.8 (18^-24) 
 Mean Peak Value (pg/ml) 641.0±200.1 (131^-1255) 386.5±134.8 (117--656) 
 Mean level at 24h (pg/ml) 187.0±63.0 (13^-335) 75.5±6.3 (63-88) 
                                                        ( ):range
Table 2. Serum bromocriptine pharmacokinetics after rectal administration of 2.5mg 
        bromocriptine (Mean±SE) 
                            Normoprolactinemia Hyperprolactinemia 
                                 (n = 1) (n=2) 
 Initial detection (h) 1 5.5±3.2 (1^-10) 
 Time to peak (h) 7 10.0±5.7 (2^-18) 
 Peak Value (pg/ml) 364 314.5±3.9 (309-320) 
 Level at 24h (pg/ml) 37 192 (N .D.---192) 
                                                       N.D. not detectable
Table 3. Serum prolactin levels following vaginal administration of 2.5mg bromo-
        criptine (Mean±SE) 
                            Normoprolactinemia Hyperprolactinemia 
                                 (n=4) (n = 2)
 Mean baseline (ng/ml) 16.7±2.2 (11.1-21.1) 56.2±2.9 (52.1^-60.3) 
 Maximun decline (h) 11.3±1.1 (8'--14) 21.0±1.5 (18-24) 
 Reduction rate at 67.7±3.4 (56.9^-73.9) 44.8±0.7 (43.4-46.1)  maximun decline (%) 
 Reduction rate at 24h (%) 27.3±6.0 (12.6^-45.2) 44.6±0.7 (43.3-45.9) 
                                                         
( ) :range
Table 4. Serum prolactin levels following rectal administration of 2.5mg bromo-
        criptine (Mean±SE) 
                            Normoprolactinemia Hyperprolactinemia 
                                 (n = 1) (n = 2)
 Baseline (ng/ml) 13.9 42.9±3.6 (37.8-48.0) 
 Maximum decline (h) 8 17.0±3.5 (12^-22) 
 Reduction rate at 38
.1 21.0±10.4 (6.3-35.6)  maximun decline (%o) 
 Reduction rate at 24h (%) 10* 32.9, 14.8* 
                                                                      :increase
respectively. Maximum PRL reduction rate was 
67.7 ± 3.4% at 11.3 ± 1.1 hours and 44.8 7% at 
21.0 ± 1.5 hours in the normoprolactinemic and 
hyperprolactinemic groups, respectively. The 
hyperprolactinemic group required a greater 
length of time to reach maximum PRL reduction 
rate than the normoprolactinemic group (p< 
0.05). The inhibitory effect of bromocriptine on 
PRL was remarkable in normoprolactinemic 
subjects (p<0.05). But PRL reduction rate at 
24 hours in the hyperproiactinemic group was 
higher than in the normoprolactinemic group. 
Therefore, bromocriptine appears to have a 
greater inhibiting effect on PRL in hyper-
prolactinemic women.
 Table 4 presents blood PRL levels following 
the rectal administration of bromocriptine. 
Basal level of blood PRL in the normopro-
lactinemic and hyperprolactinemic groups was 
13.9 ng/ml and 42.9 ± 3.6 ng/ml, respectively. 
Maximum PRL reduction rate was 38.1% at 8 
hours and 21.0 ± 10.4% at 17.0 ± 3.5 hours in the 
normoprolactinemic and hyperprolactinemic 
groups, respectively. The hyperprolactinemic 
group required a greater length of time to reach 
maximum PRL reduction rete than the 
normoprolactinemic group in both methods of
administration. The inhibitory effect of bromo-
criptine on PRL in the normoprolactinemic 
group was greater than in the hyperpro-
lactinemic group. At 24 hours, only one 
hyperprolactinemic subject showed PRL 
suppression. On the contrary, the remaining 
hyperprolactinemic subjects and the normopro-
lactinemic subjects showed an increased 
reduction rate of 14.8% and 10%, respectively. 
 The following side effects were reported by 
subjects in this study. Only transient general 
fatigue, nasal disturbances or headaches were 
experienced by subjects in the normopro-
lactinemic group. Amongst subjects in the 
hyperprolactinemic group,three subjects who 
had previous oral treatment and had 
subsequently suffered vomiting upon the first 
treatment day, reported no side effects after 
vaginal (2 subjects) or rectal (1 subject) 
treatments.
        DISCUSSION 
 Because of gastric absorption, oral admin-
istration of bromocriptine is frequently 
accompanied by gastrointestinal side effects 
such as nausea and vomiting because of which 
treatment is discontinued. Vaginal or rectal
administration rarely produces such side effects 
since the drug does not pass through the 
gastrointestinal tract. In this study, bromo-
criptine was adminstered by vaginal or rectal 
route and no gastrointestinal side effects were 
observed. Patients who had previously suffered 
from side effects by oral administration, had no 
side effects, supporting the view that vaginal 
or rectal routes of administration are superior 
methods of administration. However, further 
investigations are needed to determine the 
absorption and efficacy of bromocriptine. The 
mean peak value of blood concentration of 
bromocriptine was more than 300 pg/ml in both 
vaginal and rectal routes of administration. 
From a viewpoint of the PRL reduction rate, a 
single dose of bromocriptine appears to be 
effective for treatment of hyperprolactinemic 
patients. Administration by the vaginal route 
resulted in a higher blood concentration of 
bromocriptine and a greater PRL reduction rate 
than by the rectal route. Furthermore, by 
analysis of PRL kinetics at 24 hours after 
administration, it was found that PRL was 
suppressed. in all subjects who received 
bromocriptine by vaginal administration. 
 Conversely, rectal administration of bromo-
criptine increased PRL in two of three subjects, 
implying that the period of PRL inhibition is 
longer when bromocriptine was administered 
vaginally than rectally. Although it is not 
known what contributes to this observed 
difference, difference in absorption route may 
be one reason. When a drug is administered 
by vaginal route, it avoids the "first pass" 
through the liver. In comparison, by the rectal 
route the drug passes through the liver, thus 
lowering serum bromocriptine concentrations 
and diminishing its efficacy. Additionally, it is 
difficult for patients to administer brorno-
criptine rectally themselves. Therefore, vaginal 
administration is a better method than rectal 
administration. However, there was a large 
difference (117 pg/ml-1255 pg/ml) observed in 
serum bromocriptine cocentrations amongst 
subjects who received vaginal administration. 
In all cases of vaginal administration, loss of 
bromocriptine from the vagina was not 
observed, therefore individual variation may 
exist in the absorption from the vaginal mucosa.
For poor absorption cases, a greater PRL 
reduction can be seen if a larger dose of 
bromocriptine is administered, because linear 
regression analysis of serum bromocriptine and 
PRL values yield a highly significant negative 
correlation (2). Comparing the PRL reduction 
rates between the normoprolactinemic and 
hyperprolactinemic groups, the former has a 
greater reduction rate than the latter in both 
routes of administration independent of serum 
bromocriptine concentrations. This may be 
explained by the difference in basal prolactin 
level. Kletzky et al. (1) reported that two of 
fifteen hyperprolactinemic patients adminstered 
with 2.5 mg vaginal bromocriptine demonstrated 
an extremely poor PRL inhibition response in 
spite of the same bromocriptine dose that was 
administered to all fifteen patients. The results 
remained the same even when the dose was 
increased to 5.0mg vaginal bromocriptine. 
        CONCLUSIONS 
 Serum bromocriptine and PRL concentrations 
and associated side effects of both vaginal and 
rectal administration of bromocriptine were 
studied. It is concluded that vaginal route of 
bromocriptine administration is useful in 
patients who can not be administered by oral 
route. In patients who can not be administered 
by vaginal route, rectal route is an alternate 
method which is inferior to the method of 
vaginal administration as judged by ease of 
insertion techinique and effeicacy. 
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